FDA grants RPD status to Anavex 2-73

The FDA grants Rare Pediatric Disease (RPD) designation to Anavex Life Sciences’ (NASDAQ:AVXL) lead drug Anavex 2-73 (blarcamesine) for the treatment of a rare inherited neurological disorder called Rett syndrome that affects mostly girls.

RPD Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.

Phase 2 studies are in process.

Shares up 7% premarket on light volume.

https://seekingalpha.com/news/3519189-fda-grants-rpd-status-anavex-2minus-73-shares-ahead-7-percent-premarket